Autologous cancer vaccine: A novel formulation

Microbiology and Immunology

Volumn 47, Issue 4, 2003, Pages 255-263

  Ohno, Tadao ^a,b  

^a INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^b Cell Medicine Inc   (Japan)

Author keywords

Clinical trial; Hepatocellular carcinoma; Immunotherapy; Tumor vaccine

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; TUBERCULIN;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; AUTOTRANSPLANTATION; BRAIN TUMOR; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER TISSUE; CELL ACTIVITY; CELL CULTURE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DESQUAMATION; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; PRURITUS; SHORT SURVEY; TREATMENT OUTCOME; TUMOR RECURRENCE; VACCINATION;

EID: 0037266890     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2003.tb03393.x     Document Type: Short Survey

References (45)

1. Albert, M.L., Pearce, S.F., Francisco, L.M., Sauter, B., Roy, P., Silverstein, R.L., and Bhardwaj, N. 1998. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188: 1359-1368.
2. Berd, D., Maguire, H.C., Jr., and Mastrangelo, M.J. 1986. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46: 2572-2577.
3. Berd, D., Maguire, H.C., Jr., McCue, P., and Mastrangelo, M.J. 1990. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol. 8: 1858-1867.
4. Coutelle, C., Douar, A.M., Colledge, W.H., and Froster, U. 1995. The challenge of fetal gene therapy. Nat. Med. 1: 864-866.
5. Crowley, N.J., Darrow, T.L., Quinn-Allen, M.A., and Seigler, H.F. 1991. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells - evidence for restriction by a dominant HLA-A allele. J. Immunol. 146:1692-1699.
6. + T cells in vitro. Eur. J. Immunol. 25: 1274-1284.
7. De Bruijn, M.L.H., Peterson, P.A., and Jackson, M.R. 1996. Induction of heat-stable antigen expression by phagocytosis is involved in in vitro activation of unprimed CTL by macrophages. J. Immunol. 156: 2686-2692.
8. Falo, L.D., Jr., Kovacsovics-Bankowski, M., Thompson, K., and Rock, K.L. 1995. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1: 649-653.
9. Fisher, R.I., Coltman, C.A., Jr., Doroshow, J.H., Rayner, A.A., Hawkins, M.J., Mier, J.W., Wiernik, P., McMannis, J.D., Weiss, G.R., Margolin, K.A., Gemlo, B.T., Hoth, D.F., Parkinson, D.R., and Paietta, E. 1988. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells - a phase II clinical trial. Ann. Intern. Med. 108: 518-523.
10. Gallucci, S., Lolkema, M., and Matzinger, P. 1999. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5: 1249-1255.
11. Gong, J., Chen, D., Kashiwaba, M., and Kufe, D. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3: 558-561.
12. Guo, Y., Wu, M., Chen, H., Wang, X., Liu, G., Li, G., Ma, J., and Sy, M.S. 1994. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263: 518-520.
13. Harding, C.V., and Song, R. 1994. Phagocytic processing of particulate antigen by macrophages for presentation by class I MHC molecules. J. Immunol. 153: 4925-4933.
14. Holladay, F.P., Heitz, T., and Wood, G.W. 1992. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J. Neurosurg. 77: 757-762.
15. Horiuchi, K., Tsurushima, H., Kim, B.S., Liu, S.Q., Saijo, K., Nukiwa, T., Matsumura, M., and Ohno, T. 1998. Expansion of human autologous cytotoxic T lymphocytes on fixed target tumor cells. Cytotechnology 26: 119-124.
16. Huang, L., and Li, S. 1997. Liposomal gene delivery: a complex package. Nat. Biotechnol. 15: 620-621.
17. Ikarashi, H., Fujita, K., Takakuwa, K., Kodama, S., Tokunaga, A., Takahashi, T., and Tanaka, K. 1994. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Cancer Res. 54:190-196.
18. Ioannides, C.G., and Whiteside, T. 1993. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin. Immunol. Immunopathol. 66: 91-106.
19. Johnston, D., and Bystryn, J.C. 1991. Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine. J. Natl. Cancer. Inst. 83: 1240-1245.
20. Kantor, J., Irvine, K., Abrams, S., Kaufman, H., Dipierto, J., and Schlom, J. 1992. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst. 84: 1084-1091.
21. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Sakaguchi, K., Appella, E., Yannelli, J.R., Adema, G.J., Miki, T., and Rosenberg, S.A. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U.S.A. 91: 6458-6462.
22. Kim, C., Matsumura, M., Saijo, K., and Ohno, T. 1998. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol. Immunother. 47: 90-96.
23. Kim, C.H., Todoroki, T., Matsumura, M., and Ohno, T. 2000. Eligibility of antigenic-peptide pre-loaded and fixed adhesive pripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum CEA levels. J. Cancer Res. Clin. Oncol. 126: 383-390.
24. Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B., and Rock, K.L. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. U.S.A. 90:4942-4946.
25. Lai, E.C., Fan, S.T., Lo, C.M., Chu, K.M., Liu, C.L., and Wong, J. 1995. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann. Surg. 221: 291-298.
26. Liu, S.Q., Saijo, K., Todoroki, T., and Ohno, T. 1995. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nat. Med. 1: 267-271.
27. Liu, S.Q., Shiraiwa, H., Kawai, K., Hayashi, H., Akaza, H., Kim, B.S., Oki, A., Nishida, M., Kubo, T., Hashizaki, K., Saijo, K., and Ohno, T. 1996. Tumor-specific autologous cytotoxic T lymphocytes from tissue section. Nat. Med. 2: 1283.
28. Livingston, P.O., Albino, A.P., Chung, T.J., Real, F.X., Houghton, A.N., Oettgen, H.F., and Old, L.J. 1985. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55: 713-720.
29. Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D., Melief, C.J., Ildstad, S.T., Kast, W.M., Deleo, A.B., and Lotze, M.T. 1995. Bone marrowderived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1: 1297-1302.
30. McCune, C.S., O'Donnell, R.W., Marquis, D.M., and Sahasrabudhe, D.M. 1990. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 32: 62-66.
31. Monaco, J.J. 1992. A molecular model of MHC class-I-restricted antigen processing. Immunol. Today 13: 173-179.
32. Nister, M., and Westermark, B. 1994. Human glioma cell lines, p. 17-42. In Hay, R.J., Park, J.-G., Gazdar, A. (eds), Atlas of human tumor cell lines, Academic Press, New York.
33. Pardoll, D.M. 1998. Cancer vaccines. Nat. Med. (vaccine suppl.) 4: 525-531.
34. Peng, B.G., Liu, S.Q., Kuang, M., He, Q., Totsuka, S., Huang, L., Huang, J., Lu, M.-D., Liang, L.-J., Leong, K.W., and Ohno, T. 2002. Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma. Jpn. J. Cancer Res. 93: 363-368.
35. Powles, R.L., Russell, J.A., Selby, P.J., Prentice, H.G., Jones, D.R., McElwain, T.J., and Alexander, P. 1977. Maintenance of remission in acute myelogenous leukaemia by a mixture of B.C.G. and irradiated leukaemia cells. Lancet 2: 1107-1110.
36. Protti, M.P., and Bellone, M. 1998. Immunotherapy: natural versus synthetic peptides. Immunol. Today 19: 98.
37. Rosenberg, S.A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R.A., Moen, R., Karson, E.M., Lotze, M.T., Yang, J.C., Topalian, S.L., Merino, M.J., Culver, K., Miller, A.D., Blaese, R.M., and Anderson, W.F. 1990. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323: 570-578.
38. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Chang, A.E., Avis, F.P., Leitman, S., Linehan, W.N., Robertson, C.N., Lee, R.E., Rubin, J.T., Seipp, C.A., Simpson, C.G., and White, D.E. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med, 316: 889-897.
39. Slingluff, C.L., Cox, A.L., Stover, J.M.J., Moore, M.M., Hunt, D.F., and Engelhard, V.H. 1994. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res. 54: 2731-2737.
40. Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J.C., Hodi, F.S., Liebster, L., Lam, P., Mentzer, S., Singer, S., Tanabe, K.K., Cosimi, A.B., Duda, R., Sober, A., Bhan, A., Daley, J., Neuberg, D., Parry, G., Rokovich, J., Richards, L., Drayer, J., Berns, A., Clift, S., Cohen, L.K., Mulligan, R.C., and Dranoff, G. 1998. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U.S.A. 95: 13141-13146.
41. Tjoa, B.A., and Kranz, D.M. 1994. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection. Cancer Res. 54: 204-208.
42. Tsang, K.Y., Zaremba, S., Nieroda, C.A., Zhu, M.Z., Hamilton, J.M., and Schlom, J. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87: 982-990.
43. Tsurushima, H., Liu, S.Q., Tuboi, K., Matsumura, A., Yoshii, Y., Nose, T., Saijo, K., and Ohno, T. 1999. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphosytes, Jpn. J. Cancer Res. 90: 536-545.
44. Tsurushima, H., Liu, S.Q., Tsuboi, K., Yoshii, Y., Nose, T., and Ohno, T. 1996. Induction of human cytotoxic T lymphocytes against minced tissues of glioblastoma multiforme. J. Neurosurg. 84: 258-263.
45. Wolfel, T., Herr, W., Coulie, P., Schmitt, U., Buschenfelde, K.H.M., and Knuth, A. 1993. Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones. Int. J. Cancer 54: 636-644.